Royalty Pharma Finance Receivables (Current) decreased by 8.7% to $779.84M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.8%, from $716.56M to $779.84M. Over 5 years (FY 2020 to FY 2025), Finance Receivables (Current) shows an upward trend with a 7.8% CAGR.
Growth indicates an expanding loan portfolio, while a decline may signal tighter lending standards or reduced consumer demand.
This represents the portion of customer loans or financing agreements expected to be collected within one year. It is a...
Common in automotive and heavy equipment sectors where manufacturers provide financing to facilitate vehicle sales.
finance_receivables_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $596.85M | $579.75M | $614.35M | $570.68M | $639.24M | $675.86M | $691.32M | $610.02M | $729.91M | $742.16M | $738.44M | $660.48M | $750.10M | $765.77M | $783.77M | $716.56M | $842.94M | $860.07M | $854.39M | $779.84M |
| QoQ Change | — | -2.9% | +6.0% | -7.1% | +12.0% | +5.7% | +2.3% | -11.8% | +19.7% | +1.7% | -0.5% | -10.6% | +13.6% | +2.1% | +2.4% | -8.6% | +17.6% | +2.0% | -0.7% | -8.7% |
| YoY Change | — | — | — | — | +7.1% | +16.6% | +12.5% | +6.9% | +14.2% | +9.8% | +6.8% | +8.3% | +2.8% | +3.2% | +6.1% | +8.5% | +12.4% | +12.3% | +9.0% | +8.8% |